Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01645384
Recruitment Status : Completed
First Posted : July 20, 2012
Last Update Posted : July 20, 2012
Sponsor:
Information provided by (Responsible Party):
Dr. Reddy's Laboratories Limited

Tracking Information
First Submitted Date  ICMJE July 18, 2012
First Posted Date  ICMJE July 20, 2012
Last Update Posted Date July 20, 2012
Study Start Date  ICMJE May 2009
Actual Primary Completion Date June 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 19, 2012)
Area under curve (AUC) [ Time Frame: Pre-dose at 0.00, 0.167, 0.333, 0.50, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 hours and 48.00 hours post dose. ]
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg Under Fasting Conditions
Official Title  ICMJE An Open-label, Randomized, Single Oral Dose, Two Way Crossover Bioequivalence Study of Atorvastatin Ca 40 mg Tablets of Dr.Reddy's With Lipitor® 40 mg Tablets of Pfizer in 74 Healthy, Adult, Human Subjects Under Fasting Conditions
Brief Summary The purpose of this study is to monitor clinical status, adverse events and laboratory investigations and assess relative safety and tolerance of Atorvastatin formulations under fasting conditions.
Detailed Description An open-label, randomized, single oral dose, two way crossover bioequivalence study to compare Atorvastatin Calcium 40 mg Tablets of Dr.Reddy's with Lipitor® 40 mg Tablets of Pfizer in 74 healthy, adult, human study participants under fasting conditions.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE Drug: Atorvastatin Calcium Tablets, 40 mg
Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Other Name: Lipitor® 40 mg Tablets
Study Arms  ICMJE
  • Experimental: Atorvastatin Calcium Tablets, 40 mg
    Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
    Intervention: Drug: Atorvastatin Calcium Tablets, 40 mg
  • Active Comparator: Lipitor® 40 mg Tablets
    Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
    Intervention: Drug: Atorvastatin Calcium Tablets, 40 mg
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 19, 2012)
69
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 2009
Actual Primary Completion Date June 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • He/She should provide written informed consent.
  • He/She must be a healthy adult within 18-45 years of age (inclusive).
  • He/She should have a Body mass index of ≥ 18.5 kg/m2 and ≤ 25 kg/m2, with body weight not less than 50 kg.
  • He/She should have a systolic blood pressure with upper limit of less than 140 mmHg and lower limit of more than or equal to 90 mm Hg. Similarly diastolic blood pressure with upper limit less than 90 mm Hg and lower limit more than or equal to 60 mmHg.
  • He/She must be of normal health as determined by medical history and physical examination performed within 21 days prior to the dosing of period 1.
  • He/She should have a normal ECG, chest X-ray and vital signs.
  • Availability of a study volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
  • If study volunteer is a female and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device(IUD), or abstinence. or is postmenopausal for at least 1 year. or is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the study volunteers)

Exclusion Criteria:

  • He/She is incapable of understanding the informed consent.
  • He/She has a history of hypersensitivity or idiosyncratic reaction to study drug or any other related drug.
  • He/She has any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function. Study volunteers with a history of tuberculosis, epilepsy,asthma (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for the study.
  • He/She smokes regularly more than ten cigarettes daily and has difficulty in abstaining from smoking for the duration of each study period.
  • He/She has taken over the counter or prescribed medications, including any enzyme modifying drugs or any systemic medication within the past 30 days prior to dosing in first period.
  • He/She has a history of any psychiatric illness, which may impair the ability to provide written, informed consent.
  • He/She has a history of alcohol or substance abuse within the last 5 years.
  • He/She has clinically significant abnormal values of laboratory parameters.
  • He/She has participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 3 months.
  • He/She is unable to or likely to be non-compliant with protocol requirements or restrictions.
  • He/She, in whom study drug is contraindicated for medical reasons
  • He/She is intolerant to venipuncture.
  • Female volunteer who has used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing.
  • Female volunteer demonstrates a positive pregnancy screen. Each female study volunteer will be screened for pregnancy at screening, check-in each study period. Study volunteer with a positive or inconclusive result will be withdrawn from the study.
  • Female volunteer is currently breast feeding. Female study volunteer who is pregnant, breast-feeding or who is likely to become pregnant during the study will not be allowed to participate. Female study volunteer of child bearing potential must either abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or she will not be allowed to participate.
  • He/She has a positive urine screen for drugs of abuse at the time of admission check-in for each period will be excluded from the study.
  • He/She, who meets the inclusion and exclusion criteria, will be verified by medical investigator as per source documents duly authenticated by them reflecting clinical judgment as and when required
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE India
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01645384
Other Study ID Numbers  ICMJE 01621/09-10
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Dr. Reddy's Laboratories Limited
Study Sponsor  ICMJE Dr. Reddy's Laboratories Limited
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Dr. Sudarshan Vishwanath, MD Vimta Labs Limited
PRS Account Dr. Reddy's Laboratories Limited
Verification Date July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP